In early 2020, hospitals were racing to expand intensive care capacity as COVID-19 cases climbed. The pressure was not only to add beds, but to ensure that life-support equipment, often modified on the fly, remained safe for continuous use. In critical care, a small electrical fault is not a minor defect; it is a clinical risk, and no device can be put into use until all required regulatory approvals are secured.
For patients with Acute Respiratory Distress Syndrome (ARDS), prone positioning, turning patients onto their stomachs, can improve oxygenation. But doing it manually requires time, coordination, and physical effort from already strained staff. Automated rotation systems, including specialized ICU beds, made that therapy more consistent and less labor-intensive.
Then came the complication: manufacturers began updating these systems quickly, adding new controls, displays, and usability features to meet urgent needs. Each change, however practical, required revalidation under strict safety standards. The bottleneck shifted from production to proof: could modified systems be shown, quickly and reliably, to remain safe and secure, and necessary regulatory approvals after each modification?
Turning Design Changes into Verifiable Safety
Engineering and compliance teams moved to re-evaluate updated systems against international standards such as IEC60601-1 and IEC60601-2-52. At a leading lab Services, this meant coordinating electrical safety testing, fault-condition analysis, and system reliability checks under compressed timelines.
Within this effort, Chirag Parikh led the validation work for updated ICU therapy beds. Working with cross-functional teams, he focused on core safety parameters, grounding continuity, insulation integrity, and electrical isolation, where failure can directly affect patient outcomes. His role centered on translating rapid design updates into testable, compliant configurations, so that changes in the lab did not become risks at the bedside.
Validation was not a checklist. Systems were evaluated under normal operation and under single-fault conditions, the scenarios most likely to reveal hidden risks. The aim was straightforward: ensure devices would remain safe even when something went wrong.
Working Against the Clock
Timelines that once stretched over months were compressed into weeks. Testing had to run alongside production. Access to facilities was limited, and schedules extended beyond standard hours to keep pace with demand.
More than 200 ICU therapy beds underwent revalidation during this period under the technical guidance of Chirag. Within that effort, Chirag played a coordinating role, helping set validation priorities and resolve compliance issues that could delay certification. Keeping that process moving meant hospitals continued receiving equipment without interruption.
Internal assessments indicated that maintaining validation continuity helped avoid production slowdowns at a time when delays had immediate consequences for patient care.
Building Repeatable Ways to Prove Safety
A recurring problem was the lack of standardized approaches for validating modified devices under pressure. Each design change risked restarting the process.
Teams began to formalize more repeatable methods: modular testing that isolated subsystems, and consistent procedures for verifying similar configurations. Chirag contributed to this shift by helping structure test logic and map regulatory requirements into workflows that engineers could apply repeatedly.
The effect was incremental but important. Instead of revalidating from scratch, teams could reuse logic across variations, reducing duplication while maintaining safety. These approaches carried forward as devices evolved, with validation logic reused across additional ICU configurations. In practice, testing frameworks developed during the initial phase by Chirag were applied to a broader portfolio, approaches later adopted by ArjoHuntleigh across its ICU bed systems. This enabled consistent safety verification without restarting validation for each modification.
These validated systems were then deployed across multiple healthcare institutions, including Clement J. Zablocki VA Medical Center (Wisconsin), North Kansas City Hospital (Missouri), and the University of Toledo Medical Center (Ohio). In clinical use, such systems supported critical care teams managing severe respiratory failure, where prone therapy became essential.
In one widely reported case, an ICU physician noted that a patient with life-threatening COVID-19 complications was unresponsive to conventional ventilation. The patient showed significant recovery after being placed on a rotoprone therapy bed, with the physician stating the patient “wouldn’t have made it” without the intervention. This reflects how validated ICU bed systems can directly influence patient survival in high-acuity scenarios. Their use in such settings underscores how repeatable validation frameworks can extend beyond a single project. These frameworks support ongoing device updates while maintaining compliance in real-world clinical environments.
Where Engineering Meets Outcomes
The impact of this work is measured in consistency. Patients with severe respiratory failure often require extended prone positioning. Automated systems make that therapy continuous, not intermittent.
Clinical reports during the pandemic suggested that consistent prone therapy supported oxygenation and reduced complications associated with prolonged immobility. Studies have also found that mechanically assisted positioning can reduce variability compared to manual methods, an important factor in high-acuity care.
Chirag recalls, “The question isn’t whether a system works when everything is ideal. It’s whether it remains safe when something isn’t.”
Enabling Use at Scale
Validated systems were deployed across major healthcare networks, including facilities within the United States Department of Veterans Affairs, where compliance is a prerequisite for procurement. Without verified safety, even clinically useful devices cannot be integrated at scale.
In that sense, validation is not separate from care; it enables it.
What the Pandemic Changed
The pandemic exposed a structural tension in medical device engineering: how to move quickly without compromising safety standards. Several practices proved durable:
- Integrating validation earlier in the design cycle
- Using modular testing to scale across configurations
- Emphasizing fault-condition analysis to reflect real-world use
These are not limited to one device type. They offer a way to adapt safety-critical systems when conditions demand speed.
Look Ahead
During the COVID-19 crisis, the work of validating modified ICU systems ran parallel to clinical care. It ensured that devices arriving at hospitals were not only available but dependable.
Engineers across teams carried that responsibility, translating rapid changes into verified safety. Within this effort, Chirag Parikh took primary ownership of testing, validation strategy and execution, helping keep that bridge intact between design and use.
In intensive care, safety is not assumed. It is demonstrated, repeatedly, under conditions that allow for little error. The systems that met that standard did so because they were tested to hold when conditions were least forgiving.
Be First to Comment